DR. GEORGE EARL PEOPLES, M.D.
Radiology at Roger Brooke Dr, San Antonio, TX
License number
Texas K0989
Category
Radiology
Type
Surgical Oncology
Address
Address
3851 Roger Brooke Dr, San Antonio, TX 78234
Phone
(210) 916-4235
(210) 916-5102 (Fax)
(240) 381-2036
(210) 916-5102 (Fax)
(240) 381-2036
Personal information
See more information about GEORGE EARL PEOPLES at radaris.comName
Address
Phone
819 Muncie Ave, Dallas, TX 75212
120 Geneseo Rd, San Antonio, TX 78209
16294 County Road 1322, Flint, TX 75762
22689 Hill Rd, Salado, TX 76571
PO Box 1641, McKinney, TX 75070
Professional information
Vaccine For The Prevention Of Breast Cancer Recurrence
US Patent:
2011025, Oct 20, 2011
Filed:
Dec 9, 2009
Appl. No.:
13/133487
Inventors:
George Peoples - San Antonio TX, US
Assignee:
The Henry M. Jackson Foundation for the Advancemen t of Military Medicine, Inc. - Rockville MD
International Classification:
A61K 39/00, A61P 35/00
US Classification:
4241851
Abstract:
Provided are methods to induce and maintain a protective cytotoxic T-lymphocyte response to a peptide of the HER/neu oncogene, GP2, with the effect of inducing and maintaining protective or therapeutic immunity against breast cancer in a patient in clinical remission, including patients having low to intermediate levels of HER2/neu expression. The methods comprise administering to the patient an effective amount of a vaccine composition comprising a pharmaceutically acceptable carrier, an adjuvant such as GM-CSF, and the GP2 peptide. The methods may further comprise administering a periodic booster vaccine dose as needed due to declining GP2-specific T cell immunity. Also provided are vaccine compositions for use in the methods.
Chief, Surgical Oncology At Us Army
Position:
Chief, Surgical Oncology at US Army
Location:
San Antonio, Texas Area
Industry:
Medical Practice
Work:
US Army
-
Chief, Surgical Oncology
Vaccine For The Prevention Of Breast Cancer Relapse
US Patent:
2013018, Jul 25, 2013
Filed:
Jun 27, 2012
Appl. No.:
13/534550
Inventors:
George PEOPLES - San Antonio TX, US
Assignee:
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. - Rockville MD
International Classification:
A61K 39/00, A61K 38/19
US Classification:
4241851, 424 851
Abstract:
The invention features methods to induce and maintain a protective cytotoxic T-lymphocyte response to a peptide of the HER2/neu oncogene, E75, with the effect of inducing and maintaining protective or therapeutic immunity against breast cancer in a patient in clinical remission. The methods comprise administering to the patient an effective amount of a vaccine composition comprising a pharmaceutically acceptable carrier, an adjuvant such as recombinant human GM-CSF, and the E75 peptide at an optimized dose and schedule. The methods further comprise administering an annual or semi-annual booster vaccine dose due to declining E75-specific T cell immunity. The invention also features vaccine compositions for use in the methods.
Vaccine For The Prevention Of Breast Cancer Relapse
US Patent:
8222214, Jul 17, 2012
Filed:
Apr 11, 2008
Appl. No.:
12/602214
Inventors:
George E. Peoples - San Antonio TX, US
Assignee:
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. - Rockville MD
International Classification:
A61K 38/00
US Classification:
514 194
Abstract:
The invention features methods to induce and maintain a protective cytotoxic T-lymphocyte response to a peptide of the HER2/neu oncogene, E75, with the effect of inducing and maintaining protective or therapeutic immunity against breast cancer in a patient in clinical remission. The methods comprise administering to the patient an effective amount of a vaccine composition comprising a pharmaceutically acceptable carrier, an adjuvant such as recombinant human GM-CSF, and the E75 peptide at an optimized dose and schedule. The methods further comprise administering an annual or semi-annual booster vaccine dose due to declining E75-specific T cell immunity. The invention also features vaccine compositions for use in the methods.
Dr. George E Peoples, San Antonio TX - MD (Doctor of Medicine)
Specialties:
General Surgery, Complex General Surgical Oncology
Address:
3851 Roger Brooke Dr, San Antonio 78234
(210) 916-0439 (Phone), (210) 916-5568 (Fax)
BROOKE ARMY MEDICAL CENTER
3851 Roger Brooke Dr SUITE 3600, Fort Sam Houston 78234
(210) 916-4141 (Phone), (210) 916-5076 (Fax)
(210) 916-0439 (Phone), (210) 916-5568 (Fax)
BROOKE ARMY MEDICAL CENTER
3851 Roger Brooke Dr SUITE 3600, Fort Sam Houston 78234
(210) 916-4141 (Phone), (210) 916-5076 (Fax)
Languages:
English
Education:
Medical School
Johns Hopkins University / School of Medicine
Graduated: 1988
Johns Hopkins University / School of Medicine
Graduated: 1988
George Earl Peoples, Fort Sam Houston TX
Specialties:
Surgeon
Address:
3851 Roger Brooke Dr, Fort Sam Houston, TX 78234
Board certifications:
American Board of Surgery Certification in Surgery
Chief, Surgical Oncology At Brooke Army Medical Center
Position:
Chief, Surgical Oncology at Brooke Army Medical Center
Location:
San Antonio, Texas Area
Industry:
Medical Practice
Work:
Brooke Army Medical Center
-
Chief, Surgical Oncology
Ii-Key/Her-2/Neu Hybrid Cancer Vaccine
US Patent:
2010025, Oct 7, 2010
Filed:
Dec 21, 2009
Appl. No.:
12/643509
Inventors:
Robert Humphreys - Acton MA, US
Minzhen Xu - Northborough MA, US
George E. Peoples - San Antonio TX, US
Minzhen Xu - Northborough MA, US
George E. Peoples - San Antonio TX, US
International Classification:
A61K 39/00, A61P 35/00
US Classification:
4241851, 4242771
Abstract:
Provided are methods and compositions for treating cancer in humans, the cancer being characterized by expression of Her-2/neu. The methods involve vaccinating a patient with an Ii-Key/MHC class II hybrid construct and thereby stimulating an immune response to the native Her-2/neu protein. The construct may be in the form of an Ii-Key hybrid peptide or a nucleic acid encoding an Ii-Key hybrid peptide. Methods are described wherein the cancer being treated is breast cancer. Also claimed is a pharmaceutical composition comprising an Ii-Key/MHC class II hybrid construct with and without an adjuvant. The adjuvant can include GM-CSF. The Ii-Key hybrid construct includes the LRMK [SEQ ID NO.: 2] residues of Ii-Key protein and an MHC Class II epitope of a protein or portion thereof which is used in the vaccine or a DNA encoding the same hybrid peptide.